Pfizer (PFE) Enterprise Value (2009 - 2026)

Pfizer (PFE) has reported Enterprise Value for 18 consecutive years, with $127.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 1.96% year-over-year to $127.0 billion in Q2 2026; TTM through Jun 2026 was $127.0 billion, a 1.96% increase from a year earlier, with the FY2025 full-year figure at $128.3 billion, down 1.44% from the prior year.
• Enterprise Value was $127.0 billion for Q2 2026 at Pfizer, down from $141.3 billion in the prior quarter.
• Over five years, Enterprise Value peaked at $265.7 billion in Q2 2022 and troughed at $120.4 billion in Q3 2025.
• A 5-year average of $172.2 billion and a median of $150.9 billion in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 40.02% in 2022 and tumbled 43.43% in 2023, its largest moves.
• Over 5 years, Enterprise Value stood at $265.4 billion in 2022, then sank by 43.43% to $150.2 billion in 2023, then dropped by 13.31% to $130.2 billion in 2024, then fell by 1.44% to $128.3 billion in 2025, then decreased by 0.97% to $127.0 billion in 2026.
• The last three Enterprise Value figures came in at $127.0 billion (Q2 2026), $141.3 billion (Q1 2026), and $128.3 billion (Q4 2025), per Business Quant data.